Select display options below. (Cookies need to be enabled in your browser!)
Colors: High contrast    Default    Font Size: X-Large    Large    Medium    Default    Small   
 
 
Research & Clinical Trials

Study Detail: Ophthotech 1001

Trial Description Summary : Controlled trial for safety and efficacy of intravitreal injection of E10030 (anti-platelet derived growth factor {anti-PDGF}) given in combination with Lucentis in patients with treatment naive CNV from AMD.

Basic Trial Information
Phase: 2
Disease:  Macular Degeneration (wet form)
Sponsor: Ophthotech Corp.
Protocol Number: OPH1001
Status: Enrolling

Study Duration: 24 weeks (9 visits)


Eligibility Criteria:
        Inclusion Criteria
               CNV is predominately classic or minimally classic
               BCVA 20/63-20/200
               Total lesion greater than, or equal to 5 disc areas of which 50% must be active
               OCT Cirrus > 300 or Status > 250
               IOP < 21
               Clear ocular media for photo evaluation
        Exclusion Criteria
            Ophthalmic
                  Any prior treatment for AMD (other than vitamins/minerals)
                  Any prior intravitreal treatment in study eye, regardless of indication
                  >25% of lesion made up of scar or atrophy
                  >50% of lesion made up of SRH (sub retinal hemorrhage)
                  RAP lesions
                  Presence of significant PEDs
                  Any intraocular surgery or thermal laser within 3 months of the trial
                  Any prior thermal laser in the macular region for any indication
                  Aphakia
                  Any ocular or periocular infection in the past 12 weeks
            General Medical
                  Diabetes
                  Severe cardiac disease
                  MI in past 6 months
                  CVA within 12 months
                  Major surgery within one month
                  Clinically significant renal or hepatic disease
                  Any treatment with investigational agent within one month of trial entry

The above inclusion/exclusion criteria is not complete and the study coordinator will do a complete screening.

Study Title : A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination with Lucentis in Subjects with Neovascular Age-Related Macular Degeneration

Trial Contact Information
Site: Beachwood 
Study Coordinator: Diane W. @ 216/831-5700